Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Oligonucleotide Therapy Market Growth in 2025?

The market size for oligonucleotide therapy has seen substantial growth in the past few years. The market is projected to expand from $5.55 billion in 2024 to $6.18 billion in 2025, reflecting a compound annual growth rate (CAGR) of 11.4%. The uptick in the historical period can be credited to increased investment in research and development, the introduction of rudimentary therapies, advancements in gene editing techniques, early medicinal breakthroughs, and the emergence of rnai and antisense oligonucleotide.

What Is the Forecast for the Oligonucleotide Therapy Market Size Through 2029?

In the coming years, the size of the oligonucleotide therapy market is expected to experience substantial expansion. By 2029, predictions place its worth at $9.82 billion with a 12.3% compound annual growth rate (CAGR). The factors contributing to this anticipated growth during the forecast period include investment in research and development, expansion into global markets, broadening of the therapeutic area, strategies for altering diseases, and adaptations to regulations. The forecast period is also expected to be characterized by trends such as bespoke therapies, advancements in the methods of delivery, progress in rna interference (RNAI), innovation in antisense oligonucleotide, and the integration of gene editing techniques.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3398&type=smp

What are the Key Market Players in Oligonucleotide Therapy Market and How They’re Evolving?

Major companies operating in the oligonucleotide therapy market include Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc, Gilead Sciences Inc., BioNTech SE, Moderna Inc., Biogen Inc., Jazz Pharmaceuticals plc, QIAGEN Company, Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., SomaGenics Inc., Wave Life Sciences Ltd., Exicure Inc., Avidity Biosciences Inc., Miragen Therapeutics Inc., ProQR Therapeutics NV, Regulus Therapeutics Inc., Kastle Therapeutics LLC, Santaris Pharma A/S, InteRNA Technologies B.V., Dynacure S.A., Arcturus Therapeutics Holdings Inc., Intellia Therapeutics Inc., Regeneron Pharmaceuticals Inc., Editas Medicine Inc., Evox Therapeutics Ltd., PepGen Ltd.

What Are the Primary Growth Drivers in the Oligonucleotide Therapy Market?

The increasing global prevalence of cancer is expected to fuel the expansion of the oligonucleotide therapy market in the forecast period. The American Cancer Society, for instance, predicted in January 2022 that there will be about 1.9 million new cancer patients and 609,360 cancer deaths in the US, which equates to approximately 1,670 deaths per day. The dominant types of cancer globally are lung, prostate, bowel, and breast cancer in women, collectively making up 43% of all new cases of cancer. Hence, the escalating occurrence rates of cancer worldwide are projected to stimulate the demand for oligonucleotide therapy market in the coming years.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=3398&type=smp

What Are the Leading Segments in the Global Oligonucleotide Therapy Industry?

The oligonucleotide therapy market covered in this report is segmented –

1) By Type: Antisense Oligonucleotide, Aptamer, Other Types

2) By Application: Infectious Diseases, Oncology, Neurodegenerative Disorders, Cardiovascular Diseases, Kidney Diseases, Other End-User

3) By End User: Hospitals, Research Institutes

Subsegments:

1) By Antisense Oligonucleotide: RNA-Targeted Antisense Oligonucleotides, DNA-Targeted Antisense Oligonucleotides, Chemically Modified Antisense Oligonucleotides

2) By Aptamer: DNA Aptamers, RNA Aptamers, Small Molecule Aptamers

3) By Other Types: siRNA (Small Interfering RNA), miRNA (Micro RNA), DNAzyme And Ribozymes, Synthetic Oligonucleotides For Gene Editing

What Are the Key Market Trends in the Oligonucleotide Therapy Industry?

The entities responsible for producing oligonucleotide therapy in the market are directing resources towards research and advancement in order to enhance the structure of the therapy to lessen its possible effects on patients. The freshly developed and inventive oligonucleotides provide room for precision medicine strategies and can be formulated to pinpoint any gene with minimal aftereffects. It also facilitates the targeting of sequences that are specific to individual patients and responsible for uncommon diseases. In April 2023, the FDA gave the green signal for Qalsody, an antisense oligonucleotide (ASO), purposed for the therapy of patients with amyotrophic lateral sclerosis (ALS) linked to a shift in the superoxide dismutase 1 (SOD1) gene. Qalsody hones in on SOD1 mRNA to cut back the production of SOD1 protein.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/oligonucleotides-therapy-global-market-report

What Is the Regional Outlook for the Oligonucleotide Therapy Market?

North America was the largest region in the oligonucleotide therapy market in 2024. The regions covered in the oligonucleotide therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3398

This Report Delivers Insight On:

1. How big is the oligonucleotide therapy market, and how is it changing globally?

2. Who are the major companies in the oligonucleotide therapy market, and how are they performing?

3. What are the key opportunities and risks in the oligonucleotide therapy market right now?

4. Which products or customer segments are growing the most in the oligonucleotide therapy market?

5. What factors are helping or slowing down the growth of the oligonucleotide therapy market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model